Galectin Therapeutics (GALT) Interest Expenses (2018 - 2026)

Galectin Therapeutics' Interest Expenses history runs 9 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 13.99% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $7.6 million (up 21.52% YoY), while the FY2025 annual figure was $7.3 million, up 32.29% from the prior year.
• Interest Expenses was $2.0 million for Q1 2026 at Galectin Therapeutics, up from $1.9 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.0 million in Q1 2026 to a low of $227000.0 in Q1 2022.
• Historically, Interest Expenses has averaged $1.1 million across 5 years, with a median of $1.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Interest Expenses jumped 3742.86% in 2022, then rose 12.41% in 2025.
• A 5-year view of Interest Expenses shows it stood at $308000.0 in 2022, then jumped by 175.0% to $847000.0 in 2023, then surged by 103.66% to $1.7 million in 2024, then increased by 12.41% to $1.9 million in 2025, then rose by 2.53% to $2.0 million in 2026.
• The last three Interest Expenses figures came in at $2.0 million (Q1 2026), $1.9 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.